Overview | Faculty | Agenda | Hotel Accommodations | Registration

Symposium Chair


Steven T. Rosen, MD, FACP
Director, Robert H. Lurie Cancer Center
Northwestern University
Chicago, IL

Expert Faculty


Jessica K. Altman, MD Division of Hematology/Oncology
Northwestern University
Robert H. Lurie Comprehensive Cancer Center
Chicago, IL


Bruce D. Cheson, MD
Professor of Medicine
Hematology/Oncology
Head of Hematology
Director, Hematology Research
Lombardi Comprehensive Cancer Center
Georgetown University Hospital
Washington, DC


Michael Deininger, MD, PhD
Professor of Medicine
Division of Hematology & Medical Oncology
Section Head, Center for Hematologic Malignancies
Oregon Health & Science University
Portland, OR


Madeleine Duvic, MD
Deputy Department Chair
Department of Dermatology
Professor of Medicine and Dermatology
Division of Internal Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX


Andrew Evens, MD
Division of Hematology/Oncology
Northwestern University
Robert H. Lurie Comprehensive Cancer Center
Chicago, IL


Steven D. Gore, MD
Professor of Hematology/Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, MD


André Goy, MD, MS
Chief, Lymphoma Division
The Cancer Center Hackensack University Medical Center
Hackensack, NJ


Richard A. Larson, MD
Professor of Medicine
Director of Hematologic Malignancies Clinical Research Program
The University of Chicago Medical Center
Chicago, IL


Nikhil C. Munshi, MD
Associate Professor of Medicine
Harvard Medical School
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, MA


S. Vincent Rajkumar, MD
Professor of Medicine
Division of Hematology
Department of Medicine
Mayo Clinic
Rochester, MN


Tait D. Shanafelt, MD
Associate Professor of Medicine
Division of Hematology
Department of Medicine
Mayo Clinic
Rochester, MN


Moshe Talpaz, MD
Professor, Department of Internal Medicine
Alexander J. Trotman Professor of Leukemia Research
Associate Director of Translational Research
Associate Chief/Director of Hematologic Malignancies
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI


Julie M. Vose, MD
Neumann M. and Mildred E. Harris Professor
Chief, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, NE


Jane N. Winter, MD
Professor of Medicine
Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, IL


Thomas E. Witzig, MD
Professor of Medicine
Division of Hematology
Department of Internal Medicine
Mayo Clinic
College of Medicine
Rochester, MN


Anas Younes, MD
Director, Clinical and Translational Research Program
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas M.D. Anderson Cancer Center
Houston, TX


Andrew D. Zelenetz, MD, PhD
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, NY

CHAIR

Steven T. Rosen, MD, FACP
Director, Robert H. Lurie Cancer Center
Northwestern University
Chicago, IL

Taught by the top academic experts in hematology this is THE symposium on hematology that you should attend in 2010. It contains the most up-to-date data from the recent ASH meeting. This symposium will help clinicians improve their selection of the most appropriate therapeutics, and will also help clinicians to identify the patient sub-populations of hematology who will respond to specific drug therapies.

Agenda Back to Top
May 1, 2010 – Saturday
7:00AM - 7:50AM Breakfast
7:00AM Registration
8:00AM-8:10AM Welcome and Introductions and CME Pre Test Steven Rosen
Session 1: Critical Questions in the Treatment non-Hodgkin’s Lymphoma, Peripheral T-Cell Lymphoma, Cutaneous T-Cell Lymphoma and Chronic Lymphocytic Leukemia - Session Chair: Thomas Witzig
8:10AM Challenging the dogma in the initial treatment of follicular lymphoma with a larger number of available new treatment strategies and options: are traditional paradigms still valid? Thomas Witzig
8:30AM Point-CounterPoint: Maintenance therapy with an anti-CD20 Monoclonal Antibody rather than re-treatment upon relapse is the optimal strategy for patients with follicular lymphoma who have undergone first-line therapy.
  1. Audience votes pre and post debate via ARS
  2. Expert faculty reviews the audience votes and provides their additional perspectives
 Pro: Julie Vose
Con: Jane Winter
8:50AM Case Study: A patient with relapsed follicular lymphoma. An interactive case study followed by a review of the appropriate therapeutic options after initial systemic therapy, including traditional and new therapies and stem cell transplant. Andrew Zelenetz
9:10AM Progress in the treatment of newly diagnosed patients with mantle cell lymphoma: applying the results of the newest clinical trials. André Goy
9:30AM Case Study: The treatment of relapsed mantle cell lymphoma: applying the results of the newest clinical trials. An interactive case study followed by a review of the appropriate therapeutic options after initial systemic therapy, including traditional and new therapies. Anas Younes
9:50AM BREAK  
10:05AM How do we select the optimal strategies for the treatment of newly diagnosed and also for treating relapsed or refractory patients with diffuse large B-Cell lymphoma (DLBCL)? Andrew Evens
10:25AM Current and Emerging Therapies Treatment of Peripheral T-Cell Lymphoma (PTLC) and Related Disorders. Julie Vose
10:45AM State-of-the Art Therapy for Patients with Cutaneous T-Cell Lymphoma (CTCL) Madeleine Duvic
11:10AM Additional Audience Case Studies, Panel Discussion, Q&A, and Consensus on the status of data presented on the treatment of any Non-Hodgkin’s Lymphoma and T-Cell Malignancy Session 1 Faculty
11:30AM LUNCH WITH THE EXPERTS  
12:30PM Personalizing therapies for patients with chronic lymphocytic leukemia (CLL): What are the optimal clinical applications of chemotherapies and targeted therapies in the first-line setting? Bruce Cheson
12:50PM Case Study: Relapsed or refractory CLL: what are the optimal systemic therapies for these patients? An interactive case study followed by a review of the results of the latest clinical trials evaluating the various traditional or emerging systemic treatment options for patients with relapsed or refractory CLL Tait Shanafelt
Session 2: Critical Questions in the Treatment of Myeloid Malignancies: Acute Myeloid Leukemia, Chronic Myeloid Leukemia and Myelodysplastic Syndromes - Session Chair: Michael Deininger
1:10PM Best clinical practices for treating acute myeloid leukemia (AML): How do we integrate prognostic factors into optimal treatment decision-making? Richard Larson
1:30PM Case Study: Management of a newly diagnosed patient with Acute Promyelocytic Leukemia (APL) An interactive case study followed by a review of the results of the latest clinical trials evaluating the various traditional or emerging systemic treatment options for patients with newly diagnosed APL. Jessica Altman
1:50PM How do we select the optimal systemic therapeutic options for initial therapy of patients with chronic myeloid leukemia (CML)? Michael Deininger
2:10PM Case Study: Your CML patient has relapsed after first-line systemic therapy. What are the next therapeutic options? An interactive case study followed by a review of the results of the latest clinical trials evaluating the various traditional or emerging systemic treatment options for patients with relapsed or refractory CML. Moshe Talpaz
2:30PM Myelodysplastic syndromes: How do we apply the latest clinical data in patient care? Steven Gore
2:50PM BREAK  
Session 3: Critical Questions in the Treatment of Multiple Myeloma - Session Chair: S. Vincent Rajkumar
3:10PM What are the optimal treatment strategies for transplant-eligible candidates with multiple myeloma? Nikhil Munshi
3:40PM The optimal treatment of the non-transplant candidate with multiple myeloma: what are the emerging options and optimal strategies? S. Vincent Rajkumar
4:00PM Additional Audience Case Studies, Panel Discussion, Q&A, and Consensus on the status of data presented on the treatment of AML, CML, MDS and MM. Session 3 Faculty
4:45PM Concluding Remarks and Post-Activity CME questions. Steven Rosen
5:00PM Adjourn  
Educational Grants
Sincere appreciation is extended to the following companies for their generous commercial support of this educational meeting:
Genentech
Novartis
Celgene
Eisai
Allos
Spectrum Pharmaceuticals
Seattle Genetics
Genzyme
OBR